Prosecution Insights
Last updated: November 20, 2026
Application No. 18/833,263

DISRUPTION OF SONIC HEDGEHOG-SURF4 INTERACTION FOR CANCER TREATMENT

Non-Final OA §101§102
Filed
Jul 25, 2024
Priority
Feb 14, 2022 — provisional 63/309,648 +1 more
Examiner
COFFA, SERGIO
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Hong Kong University of Science and Technology
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
7m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
465 granted / 760 resolved
+1.2% vs TC avg
Strong +32% interview lift
Without
With
+32.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
65 currently pending
Career history
823
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
34.4%
-5.6% vs TC avg
§102
16.7%
-23.3% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 760 resolved cases

Office Action

§101 §102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election/Restrictions Applicant’s election without traverse of Group I and SEQ ID NO: 6 in the reply filed on 9/25/2026 is acknowledged. Applicants elected species (i.e. SEQ ID NO: 6) was deemed to be free of the prior art. The search was extended to another species (i.e. SEQ ID NO: 8). As a result, claims 1 and 5-6 have been examined and claims 2-4 and 7-18 are withdrawn from consideration. While applicant’s elected species may read on one or more withdrawn claims, they have not been fully examined for patentability, and thus a determination of allowability cannot be made with respect to these claims at this time. Status of the Claims Claims 1-18 are pending in this application. Claims 2-4 and 7-18 are withdrawn from consideration as being drawn to a non-elected species/invention. Claims 1 and 5-6 are presently under consideration as being drawn to the elected species/invention. Claim Objections Claims 1 and 5 are objected to because of the following informalities: Claim 1 should be amended to recite “A polypeptide molecule any one of SEQ ID NOs: 6-8 and 10;or a polypeptide molecule having at least 90% sequence identity to any one of SEQ ID NOs: 6-8 and 10molecule of claim 1”. Appropriate correction is required. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1 and 5-6 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more. Claims 1 and 5-6 are directed to a product of nature. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception. The rationale for this determination is explained below: Instant claim 1 is drawn to polypeptide molecules comprising various sequences. It is noted that this rejection applies to the species examined (i.e. SEQ ID NO: 8). Claims 5-6 are drawn to a composition comprising the polypeptide and a pharmaceutically acceptable carrier and/or excipient. As evidenced by Galdes et al. (US 6884770), SEQ ID NO: 8 is a fragment of hedgehog (see SEQ ID NO: 10, columns 77-78). The Office has prepared interim guidance (2014 Interim Guidance on Patent Subject Matter Eligibility) (Federal Register/Vol. 79, No. 241, Dec. 16, 2014) for use by USPTO personnel under 35 U.S.C. 101 in view of recent U.S. Supreme Court decisions. The 2014 Interim Eligibility Guidance supersedes the March 4, 2014 Process for Subject Matter Eligibility Analysis of Claims Reciting or Involving Laws of Nature/Natural Principles, Natural Phenomena, and/or Natural Products. The current Interim Guidance provides subject eligibility test or products and processes (See Flow Chart, p. 74621): Step 1: The instant claims are directed to a statutory patent-eligible subject matter category, a composition of matter. Step 2A: The claims involve a judicial exception, a product of nature. Specifically, the claims are drawn to a fragment of the naturally occurring protein hedgehog. Step 2B: The claims do not recite additional elements that amount to significantly more that the judicial exception. Markedly different characteristics can be expressed as the product's structure, function, and/or other properties and is evaluated based on what is recited in the claim. In accordance with this analysis, a product that is purified or isolated will be eligible when there is a resultant change in characteristics sufficient to show a marked difference from the products naturally occurring counterpart. The Applicants have not shown a marked difference from the products naturally occurring counterpart. Myriad clarified that not every change to a product will result in a marked difference, and that the mere recitation of particular words (e.g., “isolated”) in the claims does not automatically confer eligibility. Id. at 2119. See also Mayo, 132 S. Ct. at 1294 (eligibility does not “depend simply on the draftsman’s art”). The instant claims do not show any additional ingredients for the composition that imparts markedly different characteristic from any naturally occurring counterparts. With respect to claims 5-6, “a pharmaceutically acceptable carrier” includes water, which is naturally occurring. Therefore, the claims are drawn to a judicial exception and are considered patent ineligible. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 5-6 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Galdes et al. (US 6884770). It is noted that in the requirement for restriction/Election filed on 8/5/2026, the Examiner requested the election of one specific polypeptide molecule by defining each and every amino acid. Applicant elected SEQ ID NO: 6. Thus, it is clear that claim 1 relates to a polypeptide molecule comprising either SEQ ID NO: 6 or SEQ ID NO: 7 or SEQ ID NO: 8 or SEQ ID NO: 10 or a sequence having at least 90% identity to any one of SEQ ID NO: 6-8 and 10. Therefore, claim 1 has been interpreted as being drawn to “A polypeptide molecule any one of SEQ ID NOs: 6-8 and 10;or a polypeptide molecule having at least 90% sequence identity to any one of SEQ ID NOs: 6-8 and 10 With respect to claim 1, Galdes et al. teach SEQ ID NO: 10 (claim 1), which comprises instant SEQ ID NO: 8. With respect to claims 5-6, Galdes et al. teach compositions comprising the polypeptide and a pharmaceutically acceptable carrier (column 49, lines 47-67). Any inquiry concerning this communication or earlier communications from the examiner should be directed to SERGIO COFFA whose telephone number is (571)270-3022. The examiner can normally be reached M-F: 6AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MELISSA FISHER can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SERGIO COFFA Ph.D./ Primary Examiner Art Unit 1658 /SERGIO COFFA/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Jul 25, 2024
Application Filed
Nov 04, 2026
Non-Final Rejection mailed — §101, §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799165
CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS
1y 2m to grant Granted Nov 17, 2026
Patent 12790379
METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASE USING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)
4y 1m to grant Granted Nov 10, 2026
Patent 12790374
METHODS FOR TREATING MYELIN ASSOCIATED DISEASES AND MITOCHONDRIA ASSOCIATED DISEASES
2y 9m to grant Granted Nov 10, 2026
Patent 12780871
POLYPEPTIDES RV3 AND RV4 HAVING ANTI-AGING FUNCTION AND APPLICATIONS THEREOF
4y 7m to grant Granted Nov 03, 2026
Patent 12780877
CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS
1y 1m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
94%
With Interview (+32.3%)
2y 11m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 760 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month